ResearcherUniversity of PittsburghNo recent work listed

Gaurav Goel

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1688-8644; OpenAlex author ID A5114374412. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: none · 2018: 1 paper

Papers 2

Neoadjuvant Nab-paclitaxel and Gemcitabine in Borderline Resectable or Locally Advanced Unresectable Pancreatic Adenocarcinoma in Patients Who Are Ineligible f… Co-author DOI 10.21873/anticanres.12692 ↗
Novel approaches in the management of pancreatic ductal adenocarcinoma: potential promises for the future. Co-author DOI 10.1186/s13045-015-0141-5 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Weijing Sun · 1 shared paper, 2015 · strength 0.11
- Paper Novel approaches in the management of pancreatic ductal adenocarcinoma: potential promises for the future. DOI 10.1186/s13045-015-0141-5 ↗
Shawn Peterson · 1 shared paper, 2018 · strength 0.07
- Paper Neoadjuvant Nab-paclitaxel and Gemcitabine in Borderline Resectable or Locally Advanced Unresectable Pancreatic Adenoca… DOI 10.21873/anticanres.12692 ↗
Peter J. Hosein · 1 shared paper, 2018 · strength 0.07
- Paper Neoadjuvant Nab-paclitaxel and Gemcitabine in Borderline Resectable or Locally Advanced Unresectable Pancreatic Adenoca… DOI 10.21873/anticanres.12692 ↗
Ching-Wei David Tzeng · 1 shared paper, 2018 · strength 0.07
- Paper Neoadjuvant Nab-paclitaxel and Gemcitabine in Borderline Resectable or Locally Advanced Unresectable Pancreatic Adenoca… DOI 10.21873/anticanres.12692 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.